First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience

Ingrid Holst Olsen; Seppo W Langer; Ida Jepsen; Maria Assens; Birgitte Federspiel; Jane Preuss Hasselby; Carsten Palnaes Hansen; Andreas Kjaer; Ulrich Knigge

doi:10.3109/0284186x.2011.582881

First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience

Ingrid Holst Olsen, Seppo W Langer, Ida Jepsen, Maria Assens, Birgitte Federspiel, Jane Preuss Hasselby, Carsten Palnaes Hansen, Andreas Kjaer, Ulrich Knigge

13 Citations (Scopus)

Abstract

Poorly differentiated neuroendocrine carcinomas (PDECs) represent highly malignant tumors with an immense tendency to metastasize and with a poor prognosis. The treatment consists of palliative chemotherapy and corresponds to the treatment of extensive stage small cell lung cancer. Material and methods. We present the patient characteristics and treatment results of 31 consecutive, chemonave patients with PDECs treated with carboplatin, etoposide, and vincristine. Results. The response rate was 52%, the disease control rate 77%, and the median overall survival 15.3 months. The one-year survival rate was 55%, and the two-year survival rate was 19%. The median progression free survival (PFS) time was 6.6 months. Survival rates did not correlate with the Ki-67 proliferation index. The treatment was well tolerated. Conclusion. Treatment results with carboplatin, etoposide, and vincristine in chemonave patients with PDECs are comparable to those in patients with SCLC. The prognosis is however poor.

Original language	English
Journal	Acta Oncologica
Volume	51
Issue number	1
Pages (from-to)	97-100
Number of pages	4
ISSN	0284-186X
DOIs	https://doi.org/10.3109/0284186x.2011.582881
Publication status	Published - Jan 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/0284186x.2011.582881

Cite this

Olsen, I. H., Langer, S. W., Jepsen, I., Assens, M., Federspiel, B., Hasselby, J. P., Hansen, C. P., Kjaer, A., & Knigge, U. (2012). First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience. Acta Oncologica, 51(1), 97-100. https://doi.org/10.3109/0284186x.2011.582881

First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience. / Olsen, Ingrid Holst; Langer, Seppo W; Jepsen, Ida et al.
In: Acta Oncologica, Vol. 51, No. 1, 01.2012, p. 97-100.

Research output: Contribution to journal › Journal article › Research › peer-review

Olsen, IH, Langer, SW, Jepsen, I, Assens, M, Federspiel, B, Hasselby, JP, Hansen, CP, Kjaer, A & Knigge, U 2012, 'First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience', Acta Oncologica, vol. 51, no. 1, pp. 97-100. https://doi.org/10.3109/0284186x.2011.582881

@article{d1a355e469854837a219a7723e03991a,

title = "First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience",

abstract = "Poorly differentiated neuroendocrine carcinomas (PDECs) represent highly malignant tumors with an immense tendency to metastasize and with a poor prognosis. The treatment consists of palliative chemotherapy and corresponds to the treatment of extensive stage small cell lung cancer. Material and methods. We present the patient characteristics and treatment results of 31 consecutive, chemonave patients with PDECs treated with carboplatin, etoposide, and vincristine. Results. The response rate was 52%, the disease control rate 77%, and the median overall survival 15.3 months. The one-year survival rate was 55%, and the two-year survival rate was 19%. The median progression free survival (PFS) time was 6.6 months. Survival rates did not correlate with the Ki-67 proliferation index. The treatment was well tolerated. Conclusion. Treatment results with carboplatin, etoposide, and vincristine in chemonave patients with PDECs are comparable to those in patients with SCLC. The prognosis is however poor.",

author = "Olsen, {Ingrid Holst} and Langer, {Seppo W} and Ida Jepsen and Maria Assens and Birgitte Federspiel and Hasselby, {Jane Preuss} and Hansen, {Carsten Palnaes} and Andreas Kjaer and Ulrich Knigge",

year = "2012",

month = jan,

doi = "10.3109/0284186x.2011.582881",

language = "English",

volume = "51",

pages = "97--100",

journal = "Acta Oncologica",

issn = "0284-186X",

publisher = "Taylor & Francis",

number = "1",

}

TY - JOUR

T1 - First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience

AU - Olsen, Ingrid Holst

AU - Langer, Seppo W

AU - Jepsen, Ida

AU - Assens, Maria

AU - Federspiel, Birgitte

AU - Hasselby, Jane Preuss

AU - Hansen, Carsten Palnaes

AU - Kjaer, Andreas

AU - Knigge, Ulrich

PY - 2012/1

Y1 - 2012/1

N2 - Poorly differentiated neuroendocrine carcinomas (PDECs) represent highly malignant tumors with an immense tendency to metastasize and with a poor prognosis. The treatment consists of palliative chemotherapy and corresponds to the treatment of extensive stage small cell lung cancer. Material and methods. We present the patient characteristics and treatment results of 31 consecutive, chemonave patients with PDECs treated with carboplatin, etoposide, and vincristine. Results. The response rate was 52%, the disease control rate 77%, and the median overall survival 15.3 months. The one-year survival rate was 55%, and the two-year survival rate was 19%. The median progression free survival (PFS) time was 6.6 months. Survival rates did not correlate with the Ki-67 proliferation index. The treatment was well tolerated. Conclusion. Treatment results with carboplatin, etoposide, and vincristine in chemonave patients with PDECs are comparable to those in patients with SCLC. The prognosis is however poor.

AB - Poorly differentiated neuroendocrine carcinomas (PDECs) represent highly malignant tumors with an immense tendency to metastasize and with a poor prognosis. The treatment consists of palliative chemotherapy and corresponds to the treatment of extensive stage small cell lung cancer. Material and methods. We present the patient characteristics and treatment results of 31 consecutive, chemonave patients with PDECs treated with carboplatin, etoposide, and vincristine. Results. The response rate was 52%, the disease control rate 77%, and the median overall survival 15.3 months. The one-year survival rate was 55%, and the two-year survival rate was 19%. The median progression free survival (PFS) time was 6.6 months. Survival rates did not correlate with the Ki-67 proliferation index. The treatment was well tolerated. Conclusion. Treatment results with carboplatin, etoposide, and vincristine in chemonave patients with PDECs are comparable to those in patients with SCLC. The prognosis is however poor.

U2 - 10.3109/0284186x.2011.582881

DO - 10.3109/0284186x.2011.582881

M3 - Journal article

C2 - 21615243

SN - 0284-186X

VL - 51

SP - 97

EP - 100

JO - Acta Oncologica

JF - Acta Oncologica

IS - 1

ER -

First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: a single institution experience

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this